Thomas S. Lam - 08 Dec 2025 Form 4 Insider Report for Astrana Health, Inc. (ASTH)

Role: Director
Signature: /s/ Kathy Diep, as Attorney-in-Fact
Issuer symbol: ASTH
Transactions as of: 08 Dec 2025
Transactions value $: -$44,506
Form type: 4
Filing time: 10 Dec 2025, 16:15:34 UTC
Previous filing: 07 Mar 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Lam Thomas S.	Director	C/O ASTRANA HEALTH, INC., 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA	/s/ Kathy Diep, as Attorney-in-Fact	10 Dec 2025	0001664499

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ASTH	Common Stock	Options Exercise	$525K	+29.5K	+6.87%	$17.78	459K	08 Dec 2025	Direct
transaction	ASTH	Common Stock	Tax liability	-$569K	-25.9K	-5.63%	$22.00	433K	08 Dec 2025	Direct	F3
holding	ASTH	Common Stock						6.13M	08 Dec 2025	By Allied Physicians of California, a Professional Medical Corporation	F1
holding	ASTH	Common Stock						1.13M	08 Dec 2025	By the Thomas and Jeanette Lam 2002 Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ASTH	Stock Option (right to buy)	Options Exercise	$0	-29.5K	-100%	$0.00	0	08 Dec 2025	Common Stock	29.5K	$17.78	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These securities are beneficially owned by Allied Physicians of California, a Professional Medical Corporation, of which the Reporting Person is the Chief Executive Officer and Chief Financial Officer and a director and stockholder. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2	These stock options were fully vested and exercisable.
F3	Includes the following shares of restricted stock, which will vest as follows (in each case subject to continuous employment with the Issuer): (i) 77,500 shares, which will vest in three equal annual installments beginning on March 5, 2026; and (ii) 26,667 shares, which will vest upon achievement of certain pre-established performance goals.